← AI Switchboard
ROBOTS · November 16, 2026
Nov 16

Remedy Robotics raises a $62m Series B led by DCVC for a stroke-treatment robot designed to run on site, remotely or on its own

By the AI Switchboard · researched and written with AI from the sources listed on this page, each point checked against its source before publishing · how we work · report a mistake

Its N1 System is not approved anywhere. Remedy plans a pivotal trial with the University of California on the way to FDA approval.

Remedy Robotics said on 16 November that it had raised $62m in Series B funding led by DCVC. New investors include UC Investments, Skip Capital and Hostplus; existing investors Build Collective by Tony Fadell, Blackbird, Divergent Capital and KdT Ventures also took part. The release gives no valuation and no total raised to date.

Remedy builds the N1 System, an AI-enabled robot and software suite for endovascular procedures, the catheter treatments used for stroke and many heart emergencies. The company says N1 is designed for on-site, remote or autonomous operation, and that the money will fund a planned pivotal clinical trial in partnership with the University of California and work toward FDA approval for neurovascular intervention. Its chief executive and co-founder, Dr David Bell, said: “Endovascular intervention is the gold standard treatment for stroke and many cardiovascular emergencies,” adding that access is limited to a small number of hospitals.

The company's path, from its own release: in October 2025 it announced what it called the world's first remote neurointerventional procedures with N1; on 16 November 2026 it raised the Series B; next comes the University of California trial, with no date given. The release is plain about where the product stands: “The N1 System is under development and is not currently available for sale or clinical use in any jurisdiction.” It follows Foundry Robotics. $100m Series A, which the Switchboard ran on 4 November.

  • Confirmed Remedy Robotics raised $62m in Series B funding led by DCVC, with UC Investments, Skip Capital and Hostplus as new investors. Remedy Robotics release (PR Newswire)
  • Claimed N1 is designed for on-site, remote or autonomous operation, and a pivotal trial with the University of California is planned. Remedy Robotics release
  • Confirmed The N1 System is under development and not available for sale or clinical use in any jurisdiction. Remedy Robotics release

Robots & physical AIMoney & markets

Today in the November 16, 2026 edition · front page